PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARTON}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Wormax film-coated tablets for cats 16/40 mg

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:

Active substances:
Milbemycin oxime 16.0 mg
Praziquantel 40.0 mg

3. PACKAGE SIZE

2 tablets
4 tablets
8 tablets
10tablets
20 tablets
30 tablets
50 tablets
100 tablets
200 tablets
500 tablets

4. TARGET SPECIES

Cats

5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Keep blister in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

C&H Generics Ltd

14. MARKETING AUTHORISATION NUMBERS

Vm 40162/5007
Vm 40162/3007

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {BLISTER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Wormax

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Milbemycin oxime 16.0 mg/tablet
Praziquantel 40 mg/tablet

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use immediately.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Wormax film-coated tablets for cats 16/40 mg

2. COMPOSITION

Each tablet contains:

Active substances:
Milbemycin oxime 16 mg
Praziquantel 40 mg

Excipients:

Titanium Dioxide (E171) 0.519 mg
Iron oxide, yellow 0.052 mg
Iron oxide, Red 0.036 mg

Film-coated tablet.
Pink/orange, round shaped tablets with a cross break line on one side.
The tablets can be divided into halves or quarters.

3. TARGET SPECIES

Cats

4. INDICATIONS FOR USE

Treatment of mixed infections by immature and adult cestodes as well as nematodes of the following species:

- Cestodes:
Dipylidium caninum
Taenia spp.
Echinococcus multilocularis

- Nematodes:
Ancylostoma tubaeforme
Toxocara cati

Prevention of heartworm disease (*Dirofilaria immitis*) if concomitant treatment against cestodes is indicated.

The veterinary medicinal product is only indicated when use against cestodes and nematodes is indicated at the same time.

5. CONTRAINDICATIONS

Do not use in cats weighing less than 1 kg.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
See also section 'Special precautions for safe use in the target species'.

6. SPECIAL WARNINGS

Special warnings:
In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the cat should be taken into account.
The possibility that other animals in the same household can be a source of re-infection should be considered, and these should be treated as necessary with an appropriate veterinary medicinal product.
In the absence of risk of co-infection with nematodes and cestodes, a narrow spectrum product should be used.
When infection with the cestode *D. caninum* has been confirmed, concomitant treatment against intermediate hosts, such as fleas and lice, should be discussed with a veterinarian to prevent re-infection.

Special precautions for safe use in the target species:
As per good veterinary practice, animals should be weighed to ensure accurate dosing.

No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Accidental ingestion of the product may be harmful.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
Dispose of unused tablet halves.
Wash hands after use.

Special precautions for the protection of the environment:
"SPECIAL PRECAUTIONS FOR DISPOSAL"

Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of people need to be obtained from the relevant competent authority.

Pregnancy and lactation:
The product can be used in breeding cats including pregnant and lactating queens.

Interaction with other medicinal products and other forms of interaction:
The concurrent use of the product with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the product at the recommended dose.
Although not recommended, the concomitant use of the product with a spot-on containing moxidectin and imidacloprid at recommended dose rates following a single application was well tolerated in one laboratory study in 10 kittens.
The safety and efficacy of the concurrent use have not been investigated in field studies.
In the absence of further studies, caution should be taken in the case of concurrent use of the product with any other macrocyclic lactone. Also, no such studies have been performed with reproducing animals.

Overdose:
In case of overdose, in addition to signs observed at the recommended dose (see section 'Adverse events'), drooling was observed. This sign will usually disappear spontaneously within a day.

Special restrictions for use and special conditions for use:
Not applicable.

Major incompatibilities:
Not applicable.

7. ADVERSE EVENTS

Cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (such as Diarrhoea, Emesis) Hypersensitivity reaction Neurological disorders (such as Ataxia and Muscle tremor) Systemic disorders (such as Lethargy)

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder, the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

For oral use.
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally with or after food.

As per good veterinary practice, animals should be weighed to ensure accurate dosing. Underdosing could result in ineffective use and may favour resistance development.

Depending on the bodyweight of the cat, the practical dosing is as follows:

Weight	**WORMAX 16mg/40 mg Tablets for cats**
1 – 2 kg	¼ tablet
> 2 - 4 kg	½ tablet
> 4 – 8 kg	1 tablet
> 8 - 12 kg	1 ½ tablets

The product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The product has a duration of heartworm prevention of one month. For regular prevention of heartworm disease the use of a monosubstance is preferred.

The need for and frequency of re-treatment should be based on professional advice and should take into account the local epidemiological situation and the animal's lifestyle.

9. ADVICE ON CORRECT ADMINISTRATION

The product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.

10. WITHDRAWAL PERIODS

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep blister in the outer carton in order to protect from light.
Keep out of sight and reach of children.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton/blister after EXP. The expiry date refers to the last day of that month.
This veterinary medicinal product does not require any special temperature storage conditions.
Shelf life after first opening the immediate packaging: use immediately'

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.
The veterinary medicinal product should not enter water courses as it may be dangerous for fish and other aquatic organisms.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned. These measures should help to protect the environment. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 40162/5007
Vm 40162/3007

Pack sizes:
1 cardboard box containing 2 tablets (1 blister strip of 2)
1 cardboard box containing 4 tablets (1 blister strip of 4 or (2 blister strips of 2)
1 cardboard box containing 10 tablets (1 blister strip of 10 or 5 blisters strips of 2)
1 cardboard box containing 20 tablets (2 blister strips of 10 or 10 blisters strips of 2)
1 cardboard box containing 50 tablets (5 blister strips of 10)
1 cardboard box containing 100 tablets (10 blister strips of 10)
Multipacks of 10 individual packs of 2 tablets
Multipacks of 10 individual packs of 20 tablets
Multipacks of 10 individual packs of 50 tablets

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder
C&H Generics Ltd
c/o Michael McEvoy and Co, Seville House,
New Dock Street
Galway
H91 CKV0
Ireland

Manufacturer responsible for batch release and contact details to report suspected adverse reactions:
Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

Telephone: +353 (0)91 841788
vetpharmacoviggroup@chanellegroup.ie

17. OTHER INFORMATION

POM-V.

Approved 03 December 2025
Gavin Hall